www.genengnews.com ·
stockwatch engene shares crater on declines in complete response rates to bladder cancer therapy
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports a clinical trial failure for enGene's bladder cancer therapy, leading to a severe stock price decline and reduced revenue expectations. The commercial mechanism is a drug-specific pipeline failure, impacting enGene's future revenue and margin. No broader sector or supply chain effects are evident beyond the company itself.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- enGene (NASDAQ: ENGN) stock fell 83% from $8.85 to $1.50 over the past week.
- Phase II LEGEND trial for detalimogene voraplasmid showed complete response rate drop from 63% to 43% at six months.
- Analysts reduced sales forecast for the drug from $1.7 billion to $350 million.
- enGene plans to present further data at American Urological Association Annual Meeting in May 2026.
- enGene continues to engage with FDA regarding findings.
detalimogene voraplasmid faces a downtrend in revenue expectations within 48h, magnitude 3. enGene's stock has already dropped 83%, limiting further downside unless new negative data emerges.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort